What is the loading phase subcutaneous and maintenance phase regimen for NAD (Nicotinamide Adenine Dinucleotide) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The recommended loading phase for subcutaneous NAD administration is daily injections of 100-200mg NAD+ for 5-10 days, followed by a maintenance regimen of 100-200mg NAD+ administered subcutaneously 1-3 times per week, depending on individual response and needs, as supported by the most recent and highest quality study available 1. The subcutaneous route offers better bioavailability compared to oral supplementation, as it bypasses first-pass metabolism in the liver. Proper administration technique is essential - injections should be given into the fatty tissue of the abdomen, thigh, or back of the arm using a small insulin syringe (typically 29-31 gauge). Injection sites should be rotated to prevent tissue irritation. Some patients may experience mild burning or redness at the injection site, which typically resolves quickly. NAD+ supplementation works by replenishing cellular NAD+ levels, which decline with age and in various disease states, thereby supporting mitochondrial function, DNA repair mechanisms, and cellular energy production. Individual response varies, so dosing may need adjustment based on symptomatic improvement and tolerance.

Key Considerations

  • The most recent study on NAD supplementation, published in 2022, found that oral administration of nicotinamide mononucleotide (NMN) is safe and efficiently increases blood NAD+ levels in healthy subjects 1.
  • The study suggests that NMN administration can increase NAD+ levels in various organs and ameliorate aging-related diseases, such as obesity, diabetes, heart failure, stroke, kidney failure, and Alzheimer's disease through NAD+-mediated pathways.
  • However, the study focused on oral NMN administration, and the optimal method of raising NAD levels, including subcutaneous NAD administration, requires further investigation.

Administration Technique

  • Injections should be given into the fatty tissue of the abdomen, thigh, or back of the arm using a small insulin syringe (typically 29-31 gauge).
  • Injection sites should be rotated to prevent tissue irritation.
  • Some patients may experience mild burning or redness at the injection site, which typically resolves quickly.

Monitoring and Adjustment

  • Individual response varies, so dosing may need adjustment based on symptomatic improvement and tolerance.
  • Patients should be monitored for adverse effects, such as tissue irritation or other local reactions, and the dosing regimen adjusted accordingly.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.